drugset / Trial / NCT01000064

Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits

NCT01000064

Phase 3 Terminated 22 enrolled Vanderbilt University Shire · collab
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this research study is to evaluate whether Vyvanse, a psychostimulant, can help with attention deficits due to traumatic brain injury (TBI). Vyvanse is currently approved for the treatment of Attention-Deficit/Hyperactivity (ADHD). The exact effects this drug may have on attention deficits caused by TBI are not known, but we expect that Vyvanse will be of some help in treating those types of problems as well. The study will utilize functional magnetic resonance imaging (fMRI) methods, as well as neurobehavioral measures, to elucidate neural mechanisms of response.

Timeline

Start
2009-10
Primary completion
2013-12
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lisdexamfetamine Dimesylate Small molecule 30 mg
Comparator Lisdexamfetamine Dimesylate Small molecule 70 mg